CCND1和myc的mRNA联合检测在乳腺癌诊断中的临床研究

Study on Clinical Application of CCND1 and myc Gene Express in Diagnosis of Breast Cancer by Combined Detection

目的建立荧光定量聚合酶链反应（FQ—PCR）法检测细胞周期蛋白D1（CCND1）基因和核内原癌（myc）基因表达水平，探讨其联合检测在乳腺癌诊断和治疗监测中的应用。方法建立FQ—PCR法，并以β2-微球蛋白为内对照测定15名健康女性体检者、30例良性乳腺疾病患者和151例乳腺癌患者外周血中CCND1和myc的表达量。结果CCND1和myc表达水平在健康女性体检者、良性乳腺疾病扣乳腺癌患者中分别为（1．45±0．12）×10^-3，（1．45±0．11）×10^-3，（4．15±1．02）×10^-3；（1．15±0．07）×10^-3，（1．15±0．08）×10^-3，（2．86±1．51）×10^-3，它们在正常对照组和良性乳腺疾病组间差异无统计学显著性意义（P〉0．05），乳腺癌组均高于前两组（P〈0．05），β2-微球蛋白在三组间差异无统计学显著性意义（P〉O．05）。CCND1和myc联合检测的灵敏度高于单个基因的检测。结论FQ—PCR技术是高灵敏度、高特异度的快速定量检测CCND1和myc的方法，两者联合检测可有效提高乳腺癌的诊断灵敏度。

Objective To evaluate the clinical application of CCND1 and myc gene in the diagnosis of breast cancer by combined detection. Methods CCND1 and mye in the clinical samples of 15 health women,30 patients with benign breast dis- ease and 151 patients with breast cancer were detected by FQ-PCR. β2-microglobin was used as internal control. Results The level of CCND1 and myc/β2-microglobin in health women,patients with benign breast disease and patients with breast cancer were（1.45±0.12）×10^-3,（1.45±0.11）×10^-3, （4. 15±1.02）×10^-3 and （1.15±0.07）×10^-3,（1.15±0.08）×10^-3, （2.86 ± 1.51）×10^-3. There were no significant difference in CCND1 and myc/β2-microglobin between normal controis and benign breast disease group（P〉0.05）. CCND1 and myc/β2-microglobin in breast cancer group were higher than those in the other groups（P〈0. 05）. There were no difference in β2-microglobin among three groups（P〉0.05）. The sensitivity of CCND1 and myc gene express by combined detection was higher than that of single gene detection. Conclusion FQ-PCR is a rapid and sensitive and specific method for quantitating CCND1 and myc. The combined detection could improve the sensitivity of diagnosis in breast cancer.